Form 4 for ENGN enGene Therapeutics Inc.
Accepted 2024-05-29 00:00:00 ET · period of report 2024-05-28 · accession 0000929638-24-002002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-29 | 2024-05-28 | ENGN | Glickman Richard M | Dir | M - OptEx | $0.89 | +120 | 24.7K | +0.5% | +$106.80 |
| D | 2024-05-29 | 2024-05-28 | ENGN | Glickman Richard M | Dir | M - OptEx | $0.00 | -120 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-05-28 | M | A | 120 | $0.89 | 24,675 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-05-28 | M | D | 120 | $0.00 | 0 | D | $0.89 · — to — | 120 Common Shares | (F1) This option is fully vested and exercisable. (F2) This option was originally due to expire December 4, 2023, however prior to that date the expiration date was extended to 120 days following the filing of enGene Holdings Inc.'s Form S-8, which was filed February 27, 2024. Accordingly, the option expiry date is June 26, 2024. |